Clinical trials: ASCVD, open to volunteers
Pre Diabetes, ASCVD
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have…
- Trial name
- NCT05579626
- Testing
- high-intensity statin arm, low-intensity statin plus ezetimibe
- Where
- 31 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.
Non-communicable Diseases (NCD), Neoplams
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.
- Conditions
- Non-communicable Diseases (NCD), Neoplams, Cancer, Lung Cancer (NSCLC)
- Trial name
- H4H (NCT07743021)
- Where
- 33 sites in Hungary
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Center for Molecular Fingerprinting Research Nonprofit LLC
Hyperlipidemia
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
This is a randomized, controlled, collaborative, multicenter, pilot implementation science study evaluating the hypothesis that algorithm- and multi-professional team-supported lipid management reduces low density…
- Trial name
- OPTIMIZE ASCVD (NCT07334834)
- Testing
- Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Colorado Prevention Center
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia, ASCVD
Improving Lipid Optimization Quality and Treatment Options in ASCVD
The goal of this project is to study different approaches to improve the utilization of guideline directed medicines to lower cholesterol in patients with or at high risk of atherosclerosis (cholesterol buildup in the arteries).
- Trial name
- NCT06960655
- Testing
- Referral to Pharmacist-Driven Medication Management Program, Best-Practice Alert
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Brigham and Women's Hospital
sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic…
- Trial name
- NCT07889245
- Testing
- FXR0906 injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Coronary Artery Disease, Atherosclerotic Cardiovascular Disease (ASCVD)
Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)
This multicenter, randomized, open-label, noninferiority trial will compare two high-sensitivity C-reactive protein (hs-CRP) target-guided colchicine strategies in 1,768 adults with very-high-risk coronary artery disease after…
- Conditions
- Coronary Artery Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Residual Inflammatory Risk
- Trial name
- NCT07920133
- Testing
- Colchicine (Colcrys®)
- Where
- China
- Volunteers
- 1,768 people
- Sponsor
- Sir Run Run Shaw Hospital
Testicular Cancer, Survivorship
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant
- Conditions
- Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease
- Trial name
- NCT05611307
- Testing
- Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Renal Insufficiency, Atherosclerosis
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy…
- Conditions
- Renal Insufficiency, Atherosclerosis, Dyslipidemia, Hypercholesterolemia
- Trial name
- NCT07524101
- Testing
- Moderate-intensity statin and ezetimibe combination therapy, High-intensity statin monotherapy
- Where
- South Korea
- Volunteers
- 1,952 people
- Sponsor
- Yonsei University
Atherosclerosis Cardiovascular Disease, ASCVD
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD.
- Conditions
- Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- Trial name
- NCT07303777
- Testing
- ABP-745 Dose A, ABP-745 Dose B, ABP-745 Dose C
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Atom Therapeutics Co., Ltd
Atherosclerotic Cardiovascular Disease, Older Patients
LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
To determine whether treating to an LDL-C target of 25 to <70 mg/dL is superior to an LDL-C target of 70 to <100 mg/dL with respect to major cardiovascular events (cardiovascular death, myocardial infarction, stroke…
- Conditions
- Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol
- Trial name
- NCT05765370
- Testing
- Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL, Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
- Where
- China
- Volunteers
- 4,200 people
- Sponsor
- China National Center for Cardiovascular Diseases
Cardiovascular Disease
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established…
- Trial name
- AZURE-Outcomes (NCT07000357)
- Testing
- AZD0780
- Where
- 1,452 sites in United States, Argentina and 34 more
- Volunteers
- 15,100 people
- Sponsor
- AstraZeneca
Wearable Device, Cardiovascular Disease
HEARTS in Sync + CardioWatch 287-2
The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync.
- Conditions
- Wearable Device, Cardiovascular Disease, ASCVD Management, CHF - Congestive Heart Failure
- Trial name
- NCT07322510
- Testing
- Remote Patient Monitoring with Corsano CardioWatch 287-2
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- Nova Scotia Health Authority
Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical…
- Trial name
- EPOCA (NCT06930885)
- Testing
- Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group
- Where
- 13 sites in Brazil
- Volunteers
- 7,713 people
- Sponsor
- Hospital do Coracao
Atherosclerotic Cardiovascular Disease (ASCVD)
Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment
The goal of this clinical trial is to learn whether an ultra-low LDL-C target (<1.0 mmol/L) can improve clinical outcomes compared with a moderately low LDL-C target (1.0-1.39 mmol/L) in Chinese patients with extreme-high-risk…
- Trial name
- TARGET-EXTREME (NCT07615296)
- Testing
- Lipid-lowering therapy targeting LDL-C <1.0 mmol/L, Lipid-lowering therapy targeting LDL-C 1.0-1.39 mmol/L
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Beijing Anzhen Hospital
Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension
Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management
The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM).
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension, Dyslipidemia
- Trial name
- TELE-CVRM (NCT07208331)
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hypercholesterolemia, Dyslipidemias
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W [≤31 days]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic…
- Conditions
- Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
- Trial name
- NCT06568471
- Testing
- Lerodalcibep
- Where
- 18 sites in China
- Volunteers
- 210 people
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Hypercholesterolemia, Hypertriglyceridemia
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.
- Conditions
- Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
- Trial name
- NCT06451770
- Testing
- VERVE-201
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 132 people
- Sponsor
- Verve Therapeutics, Inc.
Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD)
The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying…
- Trial name
- CAT-RA (NCT07315997)
- Testing
- high sensitivity cardiac troponin
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Brigham and Women's Hospital
Metabolic Syndrome, Hypertension
Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment
The goal of this observational study is to learn if a non-contact facial scan using artificial intelligence (AI) can be used to check health status in adults living in urban areas such as Jakarta.
- Conditions
- Metabolic Syndrome, Hypertension, Diabetes (DM), Tachycardia
- Trial name
- NCT07491978
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tarumanagara University